Johnson Kenneth P
Maryland Center for Multiple Sclerosis, University of Maryland, Baltimore, 11 S. Paca Street, Suite 300A, Baltimore, Maryland 21201, USA.
J Neurol Sci. 2007 May 15;256 Suppl 1:S23-8. doi: 10.1016/j.jns.2007.01.060. Epub 2007 Mar 12.
Relapses in multiple sclerosis (MS) have wide-ranging consequences for patients and should be actively controlled with an appropriate immunomodulating agent provided soon after the diagnosis of MS. Several agents with varying mechanisms of action are approved for use in treating MS. Here we take a brief look at several short- and long-term comparative trials, examining the established strengths and weaknesses of the available immunomodulators. By reviewing the existing comparisons, clinicians will better understand the factors determining when to initiate therapy with an immunomodulator and how to determine which of these treatments may best suit their patients' needs.
多发性硬化症（MS）的复发会给患者带来广泛的后果，一旦确诊MS，就应尽快使用适当的免疫调节剂进行积极控制。几种作用机制不同的药物已被批准用于治疗MS。在此，我们简要回顾几项短期和长期对比试验，审视现有免疫调节剂已明确的优缺点。通过回顾现有对比情况，临床医生将能更好地理解决定何时开始使用免疫调节剂治疗的因素，以及如何确定哪种治疗可能最适合其患者的需求。
